Cargando…
Chronic Experimental Diabetes Accelerates Urinary Elimination of Deprenyl and its Metabolites
Many diabetic patients take several medications to treat diabetes-associated complications and other ailments. The mode of elimination of these drugs and their metabolites are poorly understood. The elimination of deprenyl, a MAO-B inhibitor, used for the treatment of the early stage of Parkinson’s...
Autores principales: | Adeghate, Ernest, Sótonyi Jr, Péter, Kalász, Huba |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers Ltd.
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2709476/ https://www.ncbi.nlm.nih.gov/pubmed/19662137 http://dx.doi.org/10.2174/1874104500802010001 |
Ejemplares similares
-
Amylin Analogues in the Treatment of Diabetes Mellitus: Medicinal Chemistry and Structural Basis of its Function
por: Adeghate, Ernest, et al.
Publicado: (2011) -
Medicinal Chemistry of the Anti-Diabetic Effects of Momordica Charantia: Active Constituents and Modes of Actions
por: Singh, Jaipaul, et al.
Publicado: (2011) -
Recent Progress in the Use of Glucagon and Glucagon Receptor Antago-nists in the Treatment of Diabetes Mellitus
por: Lotfy, Mohamed, et al.
Publicado: (2014) -
Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus
por: Lotfy, Mohamed, et al.
Publicado: (2011) -
An Update on the Molecular and Cellular Basis of Pharmacotherapy in Type 2 Diabetes Mellitus
por: Mahgoub, Mohamed Omer, et al.
Publicado: (2023)